Sage Therapeutics Inc (SAGE)
139.50
-1.41 -1.00%
NASDAQ
Oct 22, 15:47
Delayed 2m
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | -- |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -12.66 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -612.93M |
| Profitability | |
| Gross Profit Margin (Quarterly) | 94.96% |
| Profit Margin (Quarterly) | -19.27K% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield (TTM) | 0% |
| Price and Valuation | |
| Market Cap | 7.206B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio (TTM) | -- |
| PE Ratio (TTM) | -- |
| Price to Book Value | 5.991 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio (Quarterly) | 0.00 |
| Free Cash Flow (Quarterly) | -135.52M |
| Return on Equity (TTM) | Upgrade |
View All SAGE News
News
-
WireHeadlineTime (ET)
-
Yahoo10/20 18:06
-
Yahoo10/14 03:42
-
Yahoo10/09 18:18
-
Business Wire10/09 06:30
-
Yahoo10/03 10:52
-
Business Wire10/02 16:30
-
Business Wire10/02 06:30
-
Yahoo09/20 14:04
-
Yahoo09/20 13:10
-
Business Wire09/05 16:31
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 02/19/2020 08:00 EST | Misc | Sage Therapeutics Inc Fourth Quarter Earnings Conference Call in 2019 |
| 02/19/2020 | Earnings | Sage Therapeutics Inc Fourth Quarter Earnings in 2019 Release |
| 11/12/2019 08:00 EST | Misc | Sage Therapeutics Inc Third Quarter Earnings Conference Call for 2019 |
| 11/12/2019 | Earnings | Sage Therapeutics Inc Third Quarter Earnings in 2019 Release |
| 08/06/2019 08:00 EDT | Misc | Sage Therapeutics Inc Second Quarter Earnings Conference Call in 2019 |
| 08/06/2019 | Earnings | Sage Therapeutics Inc Second Quarter Earnings in 2019 Release |
| 06/05/2019 09:00 EDT | Misc | Sage Therapeutics Inc Annual General Meeting in 2018 |
| 05/02/2019 08:00 EDT | Misc | Sage Therapeutics Inc First Quarter Earnings Conference Call in 2019 |
| 05/02/2019 | Earnings | Sage Therapeutics Inc First Quarter Earnings in 2019 Release |
| 02/19/2019 08:00 EST | Misc | Sage Therapeutics Inc Fourth Quarter Earnings Conference Call in 2018 |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- URL: http://www.sagerx.com
- Investor Relations URL: http://investor.sagerx.com/
- HQ State/Province: Massachusetts
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Mid Cap/Growth
- Next Earnings Release: Nov. 12, 2019
- Last Earnings Release: Aug. 06, 2019
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-547, it is in Phase 3 clinical trials for super-refractory status epilepticus; and the SAGE-217 program which is in Phase 2 clinical trials for post-partum depression, essential tremor, Parkinson's disease and major depressive disorder. The company is also developing several other compounds for treatment that is in the early stage of development.
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 139.50 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Top Fund Holders
| Symbol | Name | Weighting |
|---|---|---|
| ETCGX | Eventide Gilead C | 2.97% |
| BTEC | Principal Healthcare Innovators ETF | 2.26% |
| FBIOX | Fidelity® Select Biotechnology | 2.25% |
| THISX | T. Rowe Price Health Sciences I | 2.14% |
| HQL | Tekla Life Sciences Investors | 1.22% |
| HFMRX | Hartford MidCap R3 | 1.17% |
| FCGSX | Fidelity® Series Growth Company | 1.08% |
| HQH | Tekla Healthcare Investors | 1.07% |
| IBB | iShares Nasdaq Biotechnology ETF | 1.05% |
| UBIO | ProShares UltraPro Nasdaq Biotechnology | 0.95% |
| FGCKX | Fidelity® Growth Company K | 0.94% |
| IEIH | iShares Evolved US Innvtv Hlthcare ETF | 0.64% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- SAGE Tweets Stocktwits
Advertisement
